Tag Archives: Federal Drug Adminstration

Healthcare IPOs sputter as uncertainty, anxiety cloud–everything; what is an issuer and investor to do?

Steve’s Take: After a perfectly miserable 2016, IPO issuers have been praying for a New England Patriots-style comeback. Bob Pisani at CNN says there are reasons to be optimistic. Leading… Read more »

Japan’s Takeda leads off 2017 M&A season with gutsy deal to buy US cancer specialist Ariad for $5.2 billion; it’s expensive, but probably worth it

Japan’s Takeda Pharmaceutical Co. Ltd. agreed to acquire Ariad Pharmaceuticals Inc. (Cambridge MA) for $24 per share in cash, or an enterprise value of approximately $5.2 billion, boosting its oncology… Read more »

Mylan to Reduce Cost of EpiPen as Pressure Mounts; Not All Patients to Benefit

Mylan NV (Amsterdam) on Thursday took some steps to alleviate patients’ cost burden for its $600 EpiPen emergency allergy shots following pressure from politicians including presidential candidate Hillary Clinton, who… Read more »

FDA Panel Supports Novartis Version of Amgen Arthritis Drug

By unanimous FDA panel vote, Novartis AG’s (Basel CHE) Enbrel (etanercept) biosimilar was approved across all of its U.S. licenses. The panel, which gives nonbinding advice to the agency, voted… Read more »

GE Healthcare Barges into Cell-Therapy Arena with Swiss Buy; Where’s the FDA?

GE Healthcare (Little Chalfont GBR) just signaled its intention to build a $1 billion business which offers specialized manufacturing tools for an upcoming tidal wave of cell therapies by acquiring… Read more »